These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 30801544)

  • 1. Renal Safety of Intravenous Gadolinium-enhanced MRI in Patients Following Liver Transplantation.
    Flynn MM; Parekh AN; Parikh MR; Sood A; Shaffer KM; Runge TM; Lipowska AM; Perez SD; Sakaria SS; Subramanian RM
    Transplantation; 2019 Jun; 103(6):e159-e163. PubMed ID: 30801544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renal safety of intravenous gadolinium-enhanced magnetic resonance imaging in patients awaiting liver transplantation.
    Shaffer KM; Parikh MR; Runge TM; Perez SD; Sakaria SS; Subramanian RM
    Liver Transpl; 2015 Nov; 21(11):1340-6. PubMed ID: 25786913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the incidence of nephrogenic systemic fibrosis in patients with moderate renal insufficiency administered gadobenate dimeglumine for MRI.
    Bryant BJ; Im K; Broome DR
    Clin Radiol; 2009 Jul; 64(7):706-13. PubMed ID: 19520215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nephrogenic systemic fibrosis: change in incidence following a switch in gadolinium agents and adoption of a gadolinium policy--report from two U.S. universities.
    Altun E; Martin DR; Wertman R; Lugo-Somolinos A; Fuller ER; Semelka RC
    Radiology; 2009 Dec; 253(3):689-96. PubMed ID: 19789233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gadobenate Dimeglumine Administration and Nephrogenic Systemic Fibrosis: Is There a Real Risk in Patients with Impaired Renal Function?
    Nandwana SB; Moreno CC; Osipow MT; Sekhar A; Cox KL
    Radiology; 2015 Sep; 276(3):741-7. PubMed ID: 25875973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence of Nephrogenic Systemic Fibrosis Using Gadobenate Dimeglumine in 1423 Patients With Renal Insufficiency Compared With Gadodiamide.
    Bruce R; Wentland AL; Haemel AK; Garrett RW; Sadowski DR; Djamali A; Sadowski EA
    Invest Radiol; 2016 Nov; 51(11):701-705. PubMed ID: 26885631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quarter-dose (0.025 mmol/kg) gadobenate dimeglumine for abdominal MRI in patients at risk for nephrogenic systemic fibrosis: preliminary observations.
    de Campos RO; Heredia V; Ramalho M; De Toni MS; Lugo-Somolinos A; Fuller ER; Semelka RC
    AJR Am J Roentgenol; 2011 Mar; 196(3):545-52. PubMed ID: 21343495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective Cohort Study of Nephrogenic Systemic Fibrosis in Patients With Stage 3-5 Chronic Kidney Disease Undergoing MRI With Injected Gadobenate Dimeglumine or Gadoteridol.
    Soulez G; Bloomgarden DC; Rofsky NM; Smith MP; Abujudeh HH; Morgan DE; Lichtenstein RJ; Schiebler ML; Wippold FJ; Russo C; Kuhn MJ; Mennitt KW; Maki JH; Stolpen A; Liou J; Semelka RC; Kirchin MA; Shen N; Pirovano G; Spinazzi A
    AJR Am J Roentgenol; 2015 Sep; 205(3):469-78. PubMed ID: 26295633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Notice of Withdrawal: No Incidence of Nephrogenic Systemic Fibrosis after Gadobenate Dimeglumine Administration in Patients Undergoing Dialysis or Those with Severe Chronic Kidney Disease.
    Martin DR; Kalb B; Mittal A; Salman K; Vedantham S; Mittal PK
    Radiology; 2018 Jan; 286(1):113-119. PubMed ID: 28731375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence of immediate gadolinium contrast media reactions.
    Prince MR; Zhang H; Zou Z; Staron RB; Brill PW
    AJR Am J Roentgenol; 2011 Feb; 196(2):W138-43. PubMed ID: 21257854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of gadolinium for arterial interventions.
    Sambol EB; Van der Meer JG; Graham A; Goldstein LJ; Karwowski JK; Dayal R; Derubertis B; Kent KC
    Ann Vasc Surg; 2011 Apr; 25(3):366-76. PubMed ID: 21288688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Observational study on the safety profile of gadoterate meglumine in 35,499 patients: The SECURE study.
    Soyer P; Dohan A; Patkar D; Gottschalk A
    J Magn Reson Imaging; 2017 Apr; 45(4):988-997. PubMed ID: 27726239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imaging patients with kidney disease: how do we approach contrast-related toxicity?
    Perazella MA; Reilly RF
    Am J Med Sci; 2011 Mar; 341(3):215-21. PubMed ID: 21139495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low risk for nephrogenic systemic fibrosis in nondialysis patients who have chronic kidney disease and are investigated with gadolinium-enhanced magnetic resonance imaging.
    Chrysochou C; Power A; Shurrab AE; Husain S; Moser S; Lay J; Salama AD; Kalra PA
    Clin J Am Soc Nephrol; 2010 Mar; 5(3):484-9. PubMed ID: 20093350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Observational study on the incidence of nephrogenic systemic fibrosis in patients with renal impairment following gadoterate meglumine administration: the NSsaFe study.
    McWilliams RG; Frabizzio JV; De Backer AI; Grinberg A; Maes BD; Zobel BB; Gottschalk A
    J Magn Reson Imaging; 2020 Feb; 51(2):607-614. PubMed ID: 31287213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Absence of potential gadolinium toxicity symptoms following 22,897 gadoteric acid (Dotarem®) examinations, including 3,209 performed on renally insufficient individuals.
    Young LK; Matthew SZ; Houston JG
    Eur Radiol; 2019 Apr; 29(4):1922-1930. PubMed ID: 30276674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison between gadolinium and iodine contrast for percutaneous intervention in atherosclerotic renal artery stenosis: clinical outcomes.
    Kane GC; Stanson AW; Kalnicka D; Rosenthal DW; Lee CU; Textor SC; Garovic VD
    Nephrol Dial Transplant; 2008 Apr; 23(4):1233-40. PubMed ID: 18256017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of meglumine gadoterate (Gd-DOTA)-enhanced MRI compared to unenhanced MRI in patients with chronic kidney disease (RESCUE study).
    Deray G; Rouviere O; Bacigalupo L; Maes B; Hannedouche T; Vrtovsnik F; Rigothier C; Billiouw JM; Campioni P; Ferreiros J; Devos D; Alison D; Glowacki F; Boffa JJ; Marti-Bonmati L
    Eur Radiol; 2013 May; 23(5):1250-9. PubMed ID: 23212275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute Adverse Events Following Gadolinium-based Contrast Agent Administration: A Single-Center Retrospective Study of 281 945 Injections.
    McDonald JS; Hunt CH; Kolbe AB; Schmitz JJ; Hartman RP; Maddox DE; Kallmes DF; McDonald RJ
    Radiology; 2019 Sep; 292(3):620-627. PubMed ID: 31264948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contrast-induced acute kidney injury in cirrhotic patients. A retrospective analysis.
    Safi W; Rauscher I; Umgelter A
    Ann Hepatol; 2015; 14(6):895-901. PubMed ID: 26436362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.